This bill amends Title XIX of the Social Security Act to make coverage of lung cancer biomarker testing a mandatory Medicaid service and to require Medicaid managed care plans to include that coverage. The statutory changes insert a new paragraph into section 1905(a) listing lung cancer biomarker testing as an item of medical assistance and add language to section 1937(b)(5) to extend the requirement to benchmark‑equivalent managed care coverage.
Why it matters: the change compels states and Medicaid managed care organizations to cover molecular and biomarker tests used to guide lung cancer treatment decisions, removing an access barrier for low‑income patients but creating immediate operational and fiscal questions for state programs, plans, clinical laboratories, and oncology providers. The bill does not appropriate additional funds or define the tests that qualify, so implementation choices (and disputes) will fall to states, plans, and providers starting January 1, 2027.
At a Glance
What It Does
The bill adds 'lung cancer biomarker testing' to the list of medical assistance items in section 1905(a) of the Social Security Act and inserts a parallel requirement into section 1937(b)(5) to cover such testing in managed‑care benchmark equivalents. The statutory changes take effect January 1, 2027.
Who It Affects
State Medicaid agencies, Medicaid managed care organizations and contractors, clinical laboratories that perform genomic and biomarker assays, oncologists and cancer centers treating Medicaid enrollees, and low‑income patients with suspected or diagnosed lung cancer.
Why It Matters
By making biomarker testing a mandatory Medicaid benefit, the bill standardizes a baseline coverage obligation across states and plans and removes a common payer barrier to precision oncology for Medicaid beneficiaries. At the same time, it creates new utilization, contracting, and budget pressures without providing definitional guidance or additional federal funding.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill is narrowly focused: it amends Title XIX to add lung cancer biomarker testing to the catalog of services that states must cover under their Medicaid state plans and to require that managed‑care benchmark coverage include the same testing. Practically, that means states cannot exclude coverage of these tests for Medicaid beneficiaries who meet their clinical criteria; managed‑care plans operating under section 1937 must also include the tests in the benefit package they deliver to enrollees.
The text is short and procedural rather than technical. It does not supply a statutory definition of 'lung cancer biomarker testing,' it does not list specific genes, platforms, or CPT/HCPCS codes, and it does not prescribe clinical criteria, frequency limits, or utilization management tools.
Implementation therefore depends on existing state plan language, agency rulemaking, plan contracts, and clinical practice guidelines that states and plans choose to adopt or require.Because the bill imposes a national coverage obligation without attaching additional federal funds, states and managed‑care plans will need to absorb incremental costs through their existing financing structures. That will likely trigger changes in prior authorization policies, network arrangements with laboratories, plan formularies for companion diagnostics and targeted therapies, and rate negotiations with managed‑care contractors.
Clinical providers and labs will need to align testing orders, coding, and documentation to meet medical‑necessity and payment rules under the revised state plans.Finally, the amendment creates a legal lever: once an item is listed in section 1905(a) it is part of the mandatory Medicaid package. That limits state discretion to exclude categories of testing but leaves open disputes over which specific assays qualify, what clinical indications justify testing, and how to handle emerging technologies and expanded panels.
Those disputes are likely to be resolved through state plan amendments, contract terms with MCOs, administrative appeals, and possibly litigation or CMS guidance.
The Five Things You Need to Know
The bill inserts a new paragraph into section 1905(a) of the Social Security Act to list 'lung cancer biomarker testing' as a required item of medical assistance.
It amends section 1937(b)(5) so that managed‑care benchmark‑equivalent coverage must include lung cancer biomarker testing, tying the requirement to Medicaid managed‑care benefit packages.
The law takes effect January 1, 2027; states and MCOs must have coverage in place by that date.
The text contains no statutory definition of 'lung cancer biomarker testing' and includes no enumerated tests, genes, or billing codes, leaving those definitions to states, plans, or clinical guidance.
The bill imposes coverage obligations but provides no dedicated federal funding or enhanced matching rate for the increased testing costs.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the Act's name: 'Improving Medicaid Precision and Cancer Test Act of 2025.' This is purely stylistic but indicates the bill's policy focus on precision oncology and testing rather than broader cancer care.
Statutory adjustments to accommodate an added mandatory benefit
This technical edit changes the cross‑references in section 1902(a)(10)(A) to reflect an additional enumerated paragraph in section 1905(a). It is a housekeeping move that ensures eligibility and benefit language align once the new mandatory benefit is added.
Adds 'lung cancer biomarker testing' to the mandatory benefits list
The core policy change inserts paragraph (32) into 1905(a) (renumbering existing paragraphs as needed) to declare lung cancer biomarker testing a covered medical assistance item. Legally, listing a service in 1905(a) converts it from an optional to a mandatory Medicaid benefit, limiting state discretion to exclude the category across fee‑for‑service enrollees and those covered by state plan requirements.
Extends the requirement to managed‑care benchmark coverage
By amending 1937(b)(5), the bill requires that benchmark‑equivalent plans used under Medicaid managed care include coverage of lung cancer biomarker testing. That pulls managed‑care contractors and capitation arrangements into the coverage obligation and prevents states from delegating exclusion of the tests via benchmark design.
Effective date
Specifies that the amendments apply beginning January 1, 2027. Practically, states and managed‑care plans must operationalize coverage policies, billing procedures, and contract amendments to comply by that date; there is no phase‑in or exception period included in the text.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicaid enrollees with suspected or diagnosed lung cancer — they gain a federal‑mandated entitlement to biomarker testing that can identify actionable mutations and guide targeted therapies.
- Community oncology providers and cancer centers serving Medicaid populations — clearer payer obligations reduce denials and administrative barriers for ordering clinically indicated tests.
- Clinical and commercial laboratories that perform genomic and biomarker assays — a new, more predictable payer (Medicaid) market will likely increase test volume and revenue opportunities.
Who Bears the Cost
- State Medicaid agencies — they face higher utilization and program costs under existing matching arrangements, and must adjust budgets or reimbursement policies to accommodate increased testing.
- Medicaid managed care organizations — plans must incorporate the tests into benefit packages and may face higher claims or stricter network requirements, which can affect capitation rates and contract negotiations.
- Taxpayers (state and federal) — absent new federal appropriations, increased testing will raise Medicaid spending that is shared between states and the federal government under existing FMAP formulas.
Key Issues
The Core Tension
The central dilemma is reconciling improved access to precision oncology for low‑income patients with the fiscal and administrative burden of covering expensive and evolving diagnostic tests: guaranteeing coverage promotes equitable care but, without definitions or funding, forces states and plans to choose between restrictive use controls and absorbing potentially substantial new costs.
The bill resolves one barrier—an explicit coverage exclusion—by making lung cancer biomarker testing a mandatory Medicaid benefit, but it leaves critical implementation details unspecified. It does not define what qualifies as 'lung cancer biomarker testing' (panel vs single‑gene assays, circulating tumor DNA vs tissue testing), nor does it set clinical indications, testing frequency, or coding standards.
Those gaps transfer decisionmaking power to state Medicaid agencies, MCO contracts, and payers, which invites variability in access and possible disputes over what tests are reimbursable.
The fiscal and operational tradeoffs are immediate. States and managed‑care plans will need to weigh expanded access against program budgets, potentially tightening prior authorization, narrowing laboratory networks, or negotiating lower reimbursement rates.
Because the bill imposes a coverage obligation without additional federal funds or an altered FMAP, it creates pressure for offsets within state budgets or for adjustments in managed‑care capitation that could indirectly affect other services. Finally, the lack of enforcement mechanics, quality metrics, or data‑reporting requirements means CMS guidance, state plan amendments, and contract language will determine how uniformly beneficiaries actually receive clinically appropriate testing.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.